Synthesis of the endogenous non-reducing end heparan sulfate disaccharide for newborn screening and diagnosis of Mucopolysaccharidosis type IIIA.

Sachin Popat Gholap, Zackary Herbst, Rajan K Paranji, Michael H Gelb

Abstract read

In one paragraph

Article in Carbohydrate research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Synthesis of Heparan Sulfate Hexadecasaccharides and Their Molecular Interaction with Mycobacterial Heparin-Binding Hemagglutinin for the Detection ofJournal of the American Chemical Society · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Sachin Popat GholapDepartment of Chemistry and Biochemistry, University of Washington, Seattle, WA, 98195, USA.

Zackary HerbstEnfanos, 4000 Mason Rd, STE 300, Seattle, WA, 98195, USA.

Rajan K ParanjiDepartment of Chemistry and Biochemistry, University of Washington, Seattle, WA, 98195, USA.

Michael H GelbDepartment of Chemistry and Biochemistry, University of Washington, Seattle, WA, 98195, USA. Electronic address: gelb@uw.edu.

Funding

Multiplex Analysis of Inborn Errors of MetabolismR01DK067859 · NIDDK · UNIVERSITY OF WASHINGTON · PI GELB, MICHAEL H · 2003 to 2025

$9.8M

NIDDK NIH HHS R01 DK067859

6 · The paper itself

Abstract

Mucopolysaccharidosis IIIA (MPS IIIA) is caused by deficiency of the lysosomal enzyme heparan N-sulfatase. Newborn screening of MPS IIIA is carried out by first-tier measurement of enzyme activity followed by measurement of accumulated heparan sulfate-derived biomarker, both by tandem mass spectrometry. Here we described the synthesis of the endogenous non-reducing end disaccharide (in unlabeled and heavy isotopic form) that can be used for quantification of this biomarker in patient samples.

Indexed as

DisaccharidesHeparan SulfateMucopolysaccharidosis IIINeonatal ScreeningBiomarkersHumansInfant, NewbornBiomarkersDisaccharidesHeparan SulfateDiagnosisInborn errors of metabolismLysosomal storage diseaseMucopolysaccharidosis-IIINewborn screeningSanfilippo syndrome type A

Identifiers

PMID40580680

DOI10.1016/j.carres.2025.109584

PMCPMC12550732

What OpenQuestion holds

Textmetadata

LicenceTDM

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.